← Eichor
Condition: Neurofibroma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Neurofibroma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Phase 2 · 1 location(s) · Kevin Kim, MD · NCT07237100MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment
NA · 1 location(s) · Shengjing Hospital · NCT05957679Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06147414Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
Phase N/A · 13 location(s) · Washington University School of Medicine · NCT03141021A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Phase 1/Phase 2 · 19 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05849662Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform
Phase 3 · 29 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT07407803Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy
NA · 1 location(s) · Massachusetts General Hospital · NCT07233408Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire de Nice · NCT03893643PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Phase 1 · 5 location(s) · Pasithea Therapeutics Corp. · NCT06961565FARD (RaDiCo Cohort) (RaDiCo-FARD)
Phase N/A · 15 location(s) · Institut National de la Santé Et de la Recherche Médicale, F · NCT05954416IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Phase 2 · 1 location(s) · Fudan University · NCT06849986DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Asses
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT07298083HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Phase 2 · 1 location(s) · Shanghai Kechow Pharma, Inc. · NCT05331105Familial Investigations of Childhood Cancer Predisposition
Phase N/A · 1 location(s) · St. Jude Children's Research Hospital · NCT03050268Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Phase 1 · 2 location(s) · National Cancer Institute (NCI) · NCT04222413A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
Phase 2 · 14 location(s) · Healx Limited · NCT06541847Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)
Phase N/A · 9 location(s) · AstraZeneca · NCT07221331Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neu
NA · 1 location(s) · Centre Leon Berard · NCT05199376Natural History Study of Patients With Neurofibromatosis Type 2
Phase N/A · 1 location(s) · National Institute of Neurological Disorders and Stroke (NIN · NCT00598351Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Phase 1 · 1 location(s) · Johns Hopkins University · NCT07102394Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Phase 1 · 25 location(s) · Bristol-Myers Squibb · NCT05245500NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and S
Phase 1/Phase 2 · 7 location(s) · St. Jude Children's Research Hospital · NCT06239272A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT04872543Real-World Treatment Study of Koselugo (Selumetinib)
Phase N/A · 12 location(s) · AstraZeneca · NCT06360406Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractor
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT02390752SPEARHEAD-3 Pediatric Study
Phase 1/Phase 2 · 10 location(s) · USWM CT, LLC · NCT05642455Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Phase N/A · 3 location(s) · Universidad Nacional Autonoma de Mexico · NCT06523582MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT05735717Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Phase 2 · 6 location(s) · Scott R. Plotkin, MD, PhD · NCT04374305
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.